BB Biotech outperforms Nasdaq Biotech Index in Q2; strong USD returns, currency drag in CHF

After a turbulent start to the year, BB Biotech delivered a resilient second quarter: both share price and NAV outperformed the Nasdaq Biotech Index (NBI), supported by key milestones across several portfolio companies. The macroeconomic environment showed signs of stabilization, with steady policy rates and moderating inflation boosting market sentiment. While technology stocks rebounded sharply, the healthcare sector lagged due to renewed policy uncertainty in the US.